Hematological Malignancies

Overall Survival for Treatment Groups

7-year OS 86% in control arm compared with 89% in the 90 Y-ibritumomab arm HR = 1.50 (95% CI: 0.84 – 2.68); P = 0.478

90 Y-ibritumomab: n = 207 Median OS: > 110 mo

100

Control: n = 202 Median OS: > 113 mo

75

50

25

N F

Cumulative Percentage 90 Y-ibritumomab Control

207 202

22 26

0

0

21

42

63

84

OS From Time of Randomization (months)

90 Y-ibritumomab Control At risk:

207 202

200 192

178 175

166 152

47 45